Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | RAB9A | P51151 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | NPC1 | O15118 | 1/20 | 0.78 |
| ▸ | P4HTM | Q9NXG6 | 14/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13210581 | 0.88 | ALDH1A1 (1.00) | ALDH1A1RAB9AKDM4ENPC1P4HTM | |
| SCHEMBL30834320 | 0.88 | ALDH1A1 (1.00) | ALDH1A1RAB9AKDM4ENPC1P4HTM | |
| SCHEMBL21662065 | 0.85 | ALDH1A1 (0.71) | ALDH1A1RAB9AKDM4ENPC1P4HTM | |
| SCHEMBL30182474 | 0.85 | RAB9A (0.71) | ALDH1A1RAB9AKDM4ENPC1P4HTM | |
| SCHEMBL13210529 | 0.85 | RAB9A (0.71) | ALDH1A1RAB9AKDM4ENPC1P4HTM | |
| SCHEMBL24892187 | 0.85 | RAB9A (0.71) | ALDH1A1RAB9AKDM4ENPC1P4HTM | |
| SCHEMBL21646078 | 0.84 | ALDH1A1 (0.64) | ALDH1A1RAB9AKDM4ENPC1P4HTM | |
| SCHEMBL13210719 | 0.83 | ALDH1A1 (0.68) | ALDH1A1RAB9AKDM4ENPC1P4HTM | |
| SCHEMBL13210531 | 0.82 | RAB9A (0.67) | ALDH1A1RAB9AKDM4ENPC1P4HTM | |
| SCHEMBL9895324 | 0.81 | P4HTM (1.00) | ALDH1A1RAB9AKDM4ENPC1P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987568-B2 | Allosteric inhibitor of WEE1 kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20210309630-A1 | ALLOSTERIC INHIBITOR OF WEE1 KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-10-07 | — | — | US | disclosed |
| WO-2020028814-A1 | ALLOSTERIC INHIBITOR OF WEE1 KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309630-A1 | ALLOSTERIC INHIBITOR OF WEE1 KINASE | WEE1, WEE2, PAXBP1 | ALDH1A1 4555/4885RAB9A 2015/4885KDM4E 206/4885 |
| US-11987568-B2 | Allosteric inhibitor of WEE1 kinase | WEE1, WEE2, PAXBP1 | ALDH1A1 4555/4885RAB9A 2015/4885KDM4E 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.